Lilly cuts Canadian prices for Mounjaro and Zepbound

Eli Lilly is lowering the Canadian list prices of its diabetes drug Mounjaro and its obesity drug Zepbound by 20% or more, according to a report in the Globe and Mail that cited a note the company sent to pharmacies ^[1]. Both drugs contain tirzepatide. The new prices are set to take effect on Dec. 29, 2025 ^[1]. Reuters said it could not independently verify the report, and Lilly did not immediately respond to a request for comment ^[1].

Under the new pricing, a four-week supply of the 2.5 mg or 5 mg doses of Mounjaro or Zepbound would drop to 300 Canadian dollars, or about $217 in U.S. dollars using the exchange rate cited in the report ^[1]. The higher 7.5 mg and 10 mg doses would cost 420 Canadian dollars for a four-week supply ^[1]. The report did not specify prior Canadian prices for comparison, so the exact size of the discount for U.S. readers is not stated in the source.

The Canadian move comes shortly after Lilly lowered the U.S. price of single-dose vials of Zepbound earlier in December, a step the company said was meant to make the obesity treatment more affordable for American patients ^[1]. The source does not lay out the full financial terms of any broader U.S. pricing arrangement, so specifics beyond the vial price cut and the new Canadian figures are not yet known from the available reporting.

Why it matters for patients

For Canadian patients using Mounjaro or Zepbound, a lower list price could mean smaller out-of-pocket costs, particularly for those paying without full insurance coverage, once the change takes effect on Dec. 29 ^[1]. The size of the benefit will depend on what people were previously paying, which the source does not detail.

For U.S. patients, the Canadian price cut is a data point in a long-running comparison of how much Americans pay for the same drugs compared with people in other wealthy countries. Lilly's decision to cut both the U.S. Zepbound vial price and the Canadian list prices in the same month suggests a company-wide effort to adjust pricing in multiple markets ^[1]. But the sources here do not show whether U.S. list prices for Mounjaro or Zepbound injector pens are changing as a direct result of this Canadian announcement, so patients should not assume their own costs will shift immediately.

Insurance coverage, pharmacy benefit manager negotiations, and manufacturer discount programs often determine what a person actually pays at the counter, separate from the list price a company sets. The reporting available does not address how these Canadian changes might interact with coverage decisions made by Canadian provincial health plans or private insurers.

What happens next

The new Canadian list prices for Mounjaro and Zepbound are scheduled to begin on Dec. 29, 2025 ^[1]. Reuters noted it had not independently confirmed the details in the Globe and Mail report, and Lilly had not responded to a request for comment as of the article's publication ^[1]. Whether Lilly makes further pricing changes in the U.S. or other countries, and how the Dec. 1 U.S. Zepbound vial price cut fits into a broader pricing strategy, is not detailed in the available sources ^[1].